A cancer strategy built on doing the opposite of what's been tried before

Mesothelioma has resisted most conventional cancer treatment approaches for decades, and the disease's median survival, roughly 12 months after diagnosis, reflects just how few effective options exist for the roughly 30,000 people worldwide it kills every year. A research team at the University of Vermont has now reported early clinical trial results for a drug that takes a genuinely counterintuitive approach: rather than trying to protect cells from cancer-related cellular damage, it deliberately strips away a tumor's own internal defenses and lets that damage build until the cancer cells destroy themselves.

The findings, based on a Phase 1 clinical trial and published in Nature Communications, showed the experimental drug controlled disease progression in 67% of patients with relapsed mesothelioma, with some tumors actually shrinking, a genuinely encouraging result for a cancer where most patients have already exhausted standard treatment options by the time they'd be eligible for a trial like this one.

Why fighting cancer's chemistry the usual way keeps failing

Cancer cells generate unusually high levels of reactive oxygen species, unstable, damaging molecules produced as a byproduct of their unusually rapid metabolism. For years, one of the more intuitive cancer treatment strategies has been to give patients antioxidants, on the theory that reducing these damaging molecules should slow tumor growth. That approach has a long track record of disappointment: clinical trials testing antioxidant supplementation against cancer have largely failed, and some research has found that boosting antioxidants can actually accelerate tumor growth rather than slow it, since cancer cells rely on a certain level of oxidative signaling to sustain their aggressive proliferation.

The University of Vermont team, led by research scientist Victoria Gibson, essentially inverted that logic. Rather than trying to reduce the oxidative stress tumor cells experience, they targeted the specific enzyme those cells rely on to survive that stress in the first place: peroxiredoxin 3, or PRX3, an antioxidant protein that operates inside mitochondria, the structures responsible for generating much of a cell's energy. Cancer cells ramp up PRX3 production specifically to neutralize the reactive oxygen species their own aggressive metabolism generates. Take that protection away, and the damage the cell was already producing internally has nowhere to go.

How the drug actually works

The experimental treatment, designated RSO-021 and developed by RS Oncology in collaboration with the University of Vermont team, uses thiostrepton, a naturally occurring antibiotic, to disable PRX3. Without that protective enzyme functioning, hydrogen peroxide accumulates inside tumor cell mitochondria until the resulting damage becomes lethal to the cell. Because cancer cells already generate considerably more oxidative stress than healthy cells to begin with, they're disproportionately vulnerable to having that one remaining safety valve removed, a form of selective toxicity that gives the approach real therapeutic promise rather than simply poisoning cells indiscriminately.

Laboratory experiments backed up the underlying mechanism convincingly. When researchers completely deleted PRX3 from mesothelioma tumor cell lines, mitochondrial function declined sharply, cell growth slowed dramatically, and the cancer cells lost their ability to form tumors at all in animal models, a fairly definitive demonstration that PRX3 isn't just correlated with tumor survival, it's functionally required for it in this cancer type.

The safety question that could have killed this approach before it started

Targeting mitochondria pharmacologically carries an obvious, immediate concern: mitochondria perform essential functions in nearly every cell in the body, not just cancer cells, which raises the question of whether a drug disabling a mitochondrial protective enzyme might cause serious collateral damage to healthy tissue. Gibson addressed that concern directly, describing a common reaction from other scientists: "People will come up to us at conferences and state that you can't target the mitochondria because they're too important." Her team's counterargument rests on a specific prior finding: other research groups have shown that eliminating PRX3 in healthy mice produces no adverse phenotype at all, meaning normal, non-cancerous tissue appears to tolerate PRX3 loss without meaningful harm.

That distinction is the entire therapeutic rationale holding this approach together. Healthy cells, generating far less baseline oxidative stress than cancer cells, apparently don't depend on PRX3 nearly as heavily for survival, giving the drug a genuine, biologically grounded selectivity window rather than simply hoping cancer cells happen to be more sensitive by chance.

What the actual trial results showed

The Phase 1 trial, which enrolled patients with relapsed mesothelioma, patients who had already progressed through standard treatment lines, reported disease control in 67% of participants, alongside survival outcomes described as exceeding standard-of-care baselines for this patient population. The drug was reported to be well-tolerated even in this critically ill patient group, an important secondary finding given that RSO-021 is, by design, deliberately inducing oxidative damage inside cells, a mechanism that could plausibly carry meaningful side effects if the selectivity between healthy and cancerous tissue didn't hold up as well in actual patients as it did in laboratory models.

It's worth being precise about what a Phase 1 trial result like this does and doesn't establish. Phase 1 trials are primarily designed to assess safety and establish appropriate dosing, not to definitively prove a drug extends survival or controls disease as effectively as it would need to for approval; that confirmation requires larger, later-stage randomized trials directly comparing the drug against existing treatment options. A 67% disease control rate in a small, early-phase trial is a genuinely encouraging signal, not yet a proven therapy.

Why this could matter well beyond mesothelioma

The research team is already looking past mesothelioma specifically. Because elevated mitochondrial oxidative stress is a common feature across many cancer types, not just mesothelioma, the underlying PRX3-targeting strategy could plausibly extend to other malignancies that share the same metabolic vulnerability. Gibson is remaining at the University of Vermont as a postdoctoral researcher specifically to help initiate new research applying thiostrepton to peritoneal malignancies, including gastric cancer and other gastrointestinal cancers, in collaboration with surgical oncologist Conor O'Neill at the UVM Cancer Center.

The broader research collaboration, spanning the University of Vermont, RS Oncology, and the University of Leicester in the UK, is also developing second-generation PRX3 inhibitors designed to be more soluble than the current formulation, potentially enabling an oral tablet version that would be considerably easier to bring to market and administer than the current trial drug. If that next generation of PRX3 inhibitors proves as effective and well-tolerated as the current results suggest, the approach could eventually offer a genuinely novel treatment avenue for cancers that, like mesothelioma, have proven notoriously resistant to the antioxidant-boosting strategies the field spent years testing before this University of Vermont team decided to try the opposite approach instead.